UP.AIACT.IN
![[and more...] (3).png](https://static.wixstatic.com/media/f0525d_a8e80b852d194395a9eebf462f119e10~mv2.png/v1/crop/x_46,y_517,w_3104,h_1725/fill/w_980,h_545,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/%5Band%20more___%5D%20(3).png)
28 Stakeholders. 4 Editors. 10 Sectors. 1 Uttar Pradesh.

India's first AI Transformation Report and Matrix on the State of Uttar Pradesh, India
The AI Transformation Matrix: Problem Statements
Powered by AIACT.IN, the matrix offers a consolidated version of 77 distinct recommendations in the form of "Sectoral Playbooks" from the UP.AIACT.IN Report 2026.
Sector
Clinical Trials, Biotechnology Regulation
Sectoral Sub-issue
Life Sciences Regulatory Reform
Problem Statement
- Delays in fast tracking clinical trial clearances and fragmented Institutional Review Board (IRB) approvals across state universities stymie trial initiation.
AI Intervention Layer, defined*
*India's IT Minister once said there are 5 layers of AI (there could be more or less). Hence it becomes necessary to define which specific AI layer was targeted in our policy recommendation for this problem statement.​
- Deployment of a unified regulatory sub portal enforcing a strict, automated 45 day Service Level Agreement (SLA) for trial initiation.
Here's what we Recommend.
- Build a dedicated sub portal specifically for life sciences, leveraging the architecture of UP industrial clearance portal, Nivesh Mitra.
Possible Mandate Recommended for the Uttar Pradesh State Government
- The state must establish the Nivesh Mitra Bio Single Window to fast track clinical trial clearances, standardize IRB approvals across state universities, and align state permissions with CDSCO timelines.
Measurable Impact of our Recommendations
- Complete compliance with the 45 day SLA execution timeline for all newly filed clinical trial applications.
Possible risks
- Failure to enforce the strict 45 day SLA timeline, causing clinical applications to stagnate inside fragmented university review boards.
Possible Economic Spillover of the Policy Move
- Lowers administrative friction for international biotechnology firms, positioning the state as a high velocity jurisdiction for life sciences research.
AI Policy Severity Index*
*Derived directly from the 77 foundational structural challenges evaluated across ten industries within the UP.AIACT.IN Report, the AI Policy Severity Index functions as an evidence-based diagnostic tool designed to classify grassroots operational friction that emerges prior to the rollout of artificial intelligence systems.
Primary Severity Level
- Level 2: Organizational & Workflow Friction
Secondary Severity Level
Level 1: Systemic & Policy Ambiguity
Primary Stakeholder Group
Mid-Level Operations & Departmental Officers, Technical Architects & Systems Engineers, Executive & Policy Decision-Makers
Stakeholder Hierarchy
Tactical & Operational Management Layer
In which Chapter of the UP.AIACT.IN Report 2026 can you find this recommendation?
Chapter 8
Level 2: Organizational & Workflow Friction